Related Experiment Videos
[Radiation therapy of localized diffuse large B-cell lymphoma]
1Department of Radiation Therapy and Oncology, International Medical Center of Japan.
Nihon Igaku Hoshasen Gakkai Zasshi. Nippon Acta Radiologica
|April 16, 2003
Summary
For localized diffuse large B-cell lymphoma, combining chemotherapy with involved field radiation therapy improves outcomes. Optimal chemotherapy cycles and radiation doses require further study for personalized treatment.
Area of Science:
- Oncology
- Hematology
- Radiation Oncology
Context:
- Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma in Japan.
- Approximately 50% of DLBCL cases present as Ann-Arbor stage I or II localized disease.
- Current evidence supports combined modality treatment over chemotherapy alone for localized DLBCL.
Purpose:
- To review the current treatment strategies for localized diffuse large B-cell lymphoma.
- To discuss controversies and areas needing further investigation, including chemotherapy cycles and radiation therapy parameters.
- To emphasize the importance of prognostic factor stratification for personalized management.
Summary:
- Combined chemotherapy and involved field radiation therapy (IFRT) demonstrate superior outcomes for localized DLBCL.
- Optimal chemotherapy duration (e.g., 3 vs. 6-8 cycles of CHOP) may depend on tumor bulk.
- Radiation dose and precise definition of IFRT require clarification; doses of at least 30 Gy are common for complete remission.
Impact:
- Highlights the need for standardized definitions and protocols for involved field radiation in DLBCL.
- Underscores the necessity of further research into optimal chemotherapy regimens and radiation doses.
- Promotes tailored treatment approaches based on prognostic factors for improved patient outcomes in localized DLBCL.